

### Amendments to the Specification:

Please replace the second paragraph of page 1 with the following amended paragraph:

Only ~~one~~ bis(aziridine oxime) of Formula 1 ~~is~~ and its dimethyl homologue are known so far in the state of the art (Andrianov, V.G., Ereemeev, A.V., Zh. Org. Khim (1991), 27, 112-16; Ereemeev, A.V., Piskunova, I.P., Andrianov, V.G., Liepins, E., Khim. Geterotsikl. Soedin (1982), (4) 488-94; Musluoglu, E., Ahsen, V., J. Chem. Research (S) (1999), 142-143).

Please replace the Abstract with the following amended paragraph:

Described are new 1-aziridino-1-hydroxyiminomethyl derivatives with the general formula (I), wherein R ~~indicates any organic residue which is able to~~ is a single bond or a linker moiety capable of covalently bond bonding two aziridine oxime groups,  $R_1$  and  $R_2$  independently of one another ~~stand for a hydrogen atom or a~~ are selected from the group consisting of -H, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, -CN, -COOH, -COOCH<sub>3</sub>, -COOC<sub>2</sub>H<sub>5</sub>, -CONH<sub>2</sub>, or -C<sub>6</sub>H<sub>5</sub> group, and n is the whole number 2, as well as a method for their preparation and drugs containing these compounds provided that  $R_1$  and  $R_2$  are not both -H and provided that  $R_1$  is not -H if  $R_2$  is -CH<sub>3</sub> and  $R_1$  is not -CH<sub>3</sub> if  $R_2$  is -H The compounds of general formula (I) show ~~antitumoral action~~ antitumor activity.